Rural South Texas hospitals and physicians face mounting strain as rising uninsured rates and federal funding cuts threaten access to essential health care.
The FDA has approved rilzabrutinib (Wayrilz) as the first Bruton’s tyrosine kinase inhibitor for adults with chronic or persistent immune thrombocytopenia who have had an insufficient response to prior therapy.